JUNE 14, 2018
Dr. Michael Bevilacqua, Amicrobe’s founder and CEO, was an invited speaker and panelist at an FDA supported meeting on the topic of developing “… Emerging Non-traditional Antibiotics”.
APRIL 24, 2018
Amicrobe, Inc., Developer Of Novel Technology For Antibiotic Resistance, Adds Safety Application To Intellectual Property Portfolio
APRIL 17, 2018
Antimicrobial Innovator Amicrobe, Inc. Positions Managment Team In Anticipation Of Product Trials
OCTOBER 24, 2017
Amicrobe, Inc. announces receipt of $2.48M award from award from CARB-X to accelerate development of Amicidin-β for treatment of life-threatening infections in surgery and trauma